Tokai Pharmaceuticals Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.--Sep. 17, 2014-- Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the pricing of its initial public offering of 6,480,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Tokai. In addition, Tokai has granted the underwriters a 30-day option to purchase from the company, at the public offering price, less underwriting discounts and commissions, up to an additional 972,000 shares of common stock. Tokai's common stock is expected to begin trading on The NASDAQ Global Market on Wednesday, September 17, 2014 under the ticker symbol "TKAI."

BMO Capital Markets, Stifel and William Blair are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 16, 2014. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: BMO Capital Markets Corp., Attention: Equity Syndicate Department3 Times Square, 27th Floor, New York, NY 10036, telephone: (800) 414-3627, email: [email protected]Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720, email: [email protected]; or from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams StreetChicago, IL 60606, telephone (800) 621-0687, email:[email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


Source: Tokai Pharmaceuticals, Inc.

Investor Contact:
Tokai Pharmaceuticals
Lee Kalowski, 617-225-4305
Chief Financial Officer
[email protected]
Media Contact:
Pure Communications, Inc.
Sheryl Seapy, 949-903-4750
[email protected]